dry AMD

astellas, izervay, geographic atrophy, eye disease, phase 3 trial, primary endpoint, dry AMD

Astellas claims positive results for Izervay in geographic atrophy but remains vague on data

Anika Sharma

Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...